BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients

Conclusions• There were no consistent differences observed between placebo and BMS-986165 treatment groups in any hematologic parameters, serum chemistry (hepatic, renal, or lipid) parameters, or serum Ig isotype levels• In addition, there were no clear dose-dependent changes observed with BMS-986165 for any of the laboratory parameters investigated • Results of 4 large ongoing Phase 3 trials of BMS-986165 (NCT03624127 [POETYK-PSO-1], NCT03611751 [POETYK-PSO-2], NCT04167462 [POETYK-PSO-3], and NCT03924427) and the longterm extension study (NCT04036435) in patients with moderate to severe plaque psoriasis will provide long-term safety and laboratory data • This work was sponsored by Bristol-Myers Squibb Company.